{"id":1019573,"date":"2026-11-10T11:53:11","date_gmt":"2026-11-10T16:53:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/"},"modified":"2026-11-10T11:53:11","modified_gmt":"2026-11-10T16:53:11","slug":"wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/","title":{"rendered":"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  10, 2026  (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).<\/p>\n<p align=\"justify\">Ionis is a commercial and clinical-stage drug company. IONS\u2019 leading approved drug is TRYNGOLZA. The FDA approved TRYNGOLZA in December 2024 for patients with Familial Chylomicronemia Syndrome. On June 24, 2026, the FDA approved TRYNGOLZA as an adjunct to diet to lower someone\u2019s triglycerides in adults with hypertriglyceridemia (sHTG).<\/p>\n<p align=\"justify\">Before the market opened on November 9, 2026, IONS announced good third quarter 2026 results but said TRYNGOLZA sales for sHTG had \u201cbeen more gradual than anticipated\u2026we have identified clear opportunities to improve performance.\u201d Third quarter TRYNGOLZA sales were just $9 million and management lowered its full-year TRYNGOLZA sale guidance to $50 million from $100 &#8211; $110 million. Management kept total company 2026 revenue guidance in place. On this news, IONS\u2019 stock price plummeted $8.42 per share to $31.00, a drop of 21.4% on very heavy volume.<\/p>\n<p align=\"justify\">Investors who suffered losses trading in Ionis common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or asavett@wolfpopper.com.<\/p>\n<p align=\"justify\">Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper\u2019s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm\u2019s website at www.wolfpopper.com.<\/p>\n<p align=\"justify\">May Be Considered Attorney Advertising in Certain Jurisdictions. <br \/>Prior Results Do Not Guarantee a Similar Outcome.<\/p>\n<p align=\"justify\">Wolf Popper LLP<br \/>Adam Savett. Esq.<br \/>570 Lexington Avenue<br \/>New York, NY 10022<br \/>Tel.: (212) 451-9655<br \/>Email: asavett@wolfpopper.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDdiNGE4YjQtOGE1Zi00OGY0LTg4YjgtYTViZWM0MDg5MDk3LTEwMjkyMTktMjAyNi0xMS0xMC1lbg==\/tiny\/Wolf-Popper-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a commercial and clinical-stage drug company. IONS\u2019 leading approved drug is TRYNGOLZA. The FDA approved TRYNGOLZA in December 2024 for patients with Familial Chylomicronemia Syndrome. On June 24, 2026, the FDA approved TRYNGOLZA as an adjunct to diet to lower someone\u2019s triglycerides in adults with hypertriglyceridemia (sHTG). Before the market opened on November 9, 2026, IONS announced good third quarter 2026 results but said TRYNGOLZA sales for sHTG had \u201cbeen more gradual than anticipated\u2026we have identified clear opportunities to improve performance.\u201d Third quarter TRYNGOLZA sales were just $9 million and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1019573","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a commercial and clinical-stage drug company. IONS\u2019 leading approved drug is TRYNGOLZA. The FDA approved TRYNGOLZA in December 2024 for patients with Familial Chylomicronemia Syndrome. On June 24, 2026, the FDA approved TRYNGOLZA as an adjunct to diet to lower someone\u2019s triglycerides in adults with hypertriglyceridemia (sHTG). Before the market opened on November 9, 2026, IONS announced good third quarter 2026 results but said TRYNGOLZA sales for sHTG had \u201cbeen more gradual than anticipated\u2026we have identified clear opportunities to improve performance.\u201d Third quarter TRYNGOLZA sales were just $9 million and &hellip; Continue reading &quot;Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-10T16:53:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors\",\"datePublished\":\"2026-11-10T16:53:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/\",\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=\",\"datePublished\":\"2026-11-10T16:53:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/","og_locale":"en_US","og_type":"article","og_title":"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors - Market Newsdesk","og_description":"NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) &#8212; Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS). Ionis is a commercial and clinical-stage drug company. IONS\u2019 leading approved drug is TRYNGOLZA. The FDA approved TRYNGOLZA in December 2024 for patients with Familial Chylomicronemia Syndrome. On June 24, 2026, the FDA approved TRYNGOLZA as an adjunct to diet to lower someone\u2019s triglycerides in adults with hypertriglyceridemia (sHTG). Before the market opened on November 9, 2026, IONS announced good third quarter 2026 results but said TRYNGOLZA sales for sHTG had \u201cbeen more gradual than anticipated\u2026we have identified clear opportunities to improve performance.\u201d Third quarter TRYNGOLZA sales were just $9 million and &hellip; Continue reading \"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-10T16:53:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors","datePublished":"2026-11-10T16:53:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/"},"wordCount":270,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/","name":"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=","datePublished":"2026-11-10T16:53:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg3NDU2NSM3OTU3NDAwIzIwMTc2NDY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/wolf-popper-llp-announces-investigation-on-behalf-of-ionis-pharmaceuticals-inc-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Wolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. Investors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019573","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1019573"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1019573\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1019573"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1019573"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1019573"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}